Catalyst-owned Therapure delays IPO citing market conditions
Therapure Biopharma Inc, a Canadian biopharmaceutical company owned by Catalyst Capital Group, has decided to postpone its proposed initial public offering. The company said that while it has been "performing above expectations", and meeting positive investor feedback, the current market environment is not conducive to a public sale at this time. As reported by PE Hub Canada last month, Therapure was seeking $130 million from its IPO, which included a secondary offering by Catalyst. GMP Securities' Steve Ottaway said his firm, one of the IPO's joint bookrunners, will continue to work with Catalyst and Therapure "to evaluate capital market conditions."
4 February 2016•2 mins read
